What is HC Wainwright’s Estimate for GPCR Q3 Earnings?

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) – Equities researchers at HC Wainwright cut their Q3 2026 earnings per share (EPS) estimates for shares of Structure Therapeutics in a report issued on Friday, August 7th. HC Wainwright analyst A. Ghosh now expects that the company will earn ($0.50) per share for the quarter, down from their prior forecast of ($0.37). HC Wainwright currently has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($1.64) per share. HC Wainwright also issued estimates for Structure Therapeutics’ Q4 2026 earnings at ($0.50) EPS and FY2026 earnings at ($1.84) EPS.

Several other research firms have also issued reports on GPCR. Citizens Jmp dropped their price target on Structure Therapeutics from $113.00 to $110.00 and set a “market outperform” rating on the stock in a research report on Friday. Citigroup reiterated a “market outperform” rating on shares of Structure Therapeutics in a research note on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Friday, July 17th. Canaccord Genuity Group set a $111.00 price target on shares of Structure Therapeutics in a report on Friday. Finally, Wall Street Zen downgraded shares of Structure Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $110.91.

Structure Therapeutics Stock Up 1.3%

NASDAQ:GPCR opened at $53.81 on Tuesday. The company has a market cap of $3.82 billion, a PE ratio of -53.81 and a beta of -1.43. The business’s 50 day moving average is $47.94 and its two-hundred day moving average is $53.69. Structure Therapeutics has a 52 week low of $16.00 and a 52 week high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10).

Institutional Trading of Structure Therapeutics

Several hedge funds have recently bought and sold shares of GPCR. Sterling Capital Management LLC acquired a new position in Structure Therapeutics during the 1st quarter valued at about $28,000. State of Wyoming acquired a new stake in Structure Therapeutics in the 2nd quarter valued at approximately $28,000. CWM LLC raised its stake in Structure Therapeutics by 35.2% during the 4th quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after acquiring an additional 125 shares in the last quarter. Assetmark Inc. raised its stake in Structure Therapeutics by 21.4% during the 1st quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock valued at $123,000 after acquiring an additional 449 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey acquired a new position in Structure Therapeutics during the 4th quarter worth $127,000. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.